Announcement PDF Company Announcement IMAGION BIOSYSTEMS LIMITED ASX: IBX 1 September 2025 Dr Nina Webster Appointed to IBX Board of Directors Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging technology, is pleased to announce the appointment of Dr Nina Webster as a NonExecutive Director to the Board, effective 1 September 2025. Dr Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd (ASX: DXB), a clinical-stage biopharmaceutical company, developing a portfolio of drugs to treat inflammatory diseases. Formerly the Commercial Director for Acrux Limited (ASX: ACR) and Director of Commercialisation and Intellectual Property for Immuron Limited (ASX: IMC), Nina brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Dr Webster holds a Ph.D in Pharmaceutics, a Bachelor’s degree in Pharmacology, a Master’s degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited. Dr Webster commented "I’m honoured to join the board of Imagion Biosystems as a non-executive director and to contribute to the strategic direction and governance of the business. Imagion’s innovative approach to molecular imaging and potential early disease detection holds immense promise for improving patient outcomes. I’m excited to support the company’s mission to bring transformative diagnostic technologies to the clinic and help make a meaningful difference in people’s lives." The addition of Dr Webster to the IBX Board of Directors will further strengthen the Board’s capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies. Chair of the Board, Robert Proulx, said: “We are delighted to welcome Nina to the Board. As we continue to reshape the company to better reflect the maturing state of our business, her extensive industry knowledge and board experience will be invaluable.” Authorization & Additional Information This announcement was authorized by the Board of Imagion Biosystems Limited.  ENDS  Imagion Biosystems Limited ASX: IBX ACN 616 305 027 Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 http://www.imagionbiosystems.com/ | investor@imagionbio.com Company Announcement About Imagion Biosystems Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. For more information, visit https://imagionbiosystems.com/investor-hub/ Media & Investor Relations: Email: info@imagionbio.com AU: +61 3 9692 7222 About the MagSense® Imaging Agent Technology MagSense® technology is a new class of MRI imaging agents that improves cancer detection compared to conventional imaging technologies by adding molecular specificity without using radioactivity. MagSense® agents will be the first imaging technology to use targeted magnetic nanoparticles to tag and detect cancers allowing for visualization using MRI. This new class of imaging agents does not use ionizing radiation or radioactive tracers and improves how medical imaging can be used compared to conventional imaging methods which only identify a region of interest using anatomical or morphological features but cannot differentiate benign tumors from malignant cancer. Imagion has developed MagSense® imaging agents for three different types of cancer. The lead product has completed a Phase 1 study for the detection of nodal metastases in HER2 breast cancer and is now being advanced to a Phase 2 study. Two additional agents for prostate cancer and ovarian cancer are ready for IND-enabling studies before advancing to Phase 1 studies. Imagion Biosystems Limited ASX: IBX ACN 616 305 027 Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 http://www.imagionbiosystems.com/ | investor@imagionbio.com